2013-03-14 07:02:49 -

Actelion Pharmaceuticals Ltd /
Actelion nominates Mr. John J. Greisch for election to the Board of Directors 
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

ALLSCHWIL/BASEL,  SWITZERLAND - 14 March  2013 - Actelion Ltd  (SIX: ATLN) today
issued  the formal  invitation to  the upcoming  Annual General Meeting (AGM) of
shareholders on behalf of the Board of Directors.

At  the  AGM  the  Board  is  nominating  Mr.  John  J.  Greisch to the Board of
Directors. Mr. Greisch is currently serving as the President and Chief Executive
Officer of Hill-Rom Holdings, Inc.

Jean-Pierre  Garnier,  Chairman  of  the  Board    of  Directors, commented: "As a
current  CEO, John understands  the challenges that  face companies operating in
the  current economic and business climate. I believe John's strong track record
of  success in the  healthcare industry will  add significant practical business
acumen to Actelion's Board."

In  addition,  delivering  on  Actelion's  commitment  to value creation for all
stakeholders,  the Board  is proposing  a 25% increase  in the dividend payment,
increasing the payment to CHF 1.00 per share


AGENDA FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2013

 1. Approval of the Business Report consisting of the Annual Report, the Annual
    Statutory Accounts and the Consolidated Accounts as of 31 December 2012
 2. Appropriation of Available Earnings and Distribution Against Reserve from
    Capital Contribution
 3. Consultative Vote on Compensation Report
 4. Discharge of the Board of Directors and of the Senior Management
 5. Reduction of Share Capital by Cancellation of Repurchased Shares
 6. Board Elections
    6.1  Re-Election of Mr. Werner Henrich
    6.2 Re-Election of Mr. Armin Kessler
    6.3   Re-Election of Mr. Jean Malo
    6.4   Election of Mr. John J. Greisch as New Board Member
 7. Election of the Statutory Auditors



NOTES TO SHAREHOLDERS

The Annual General Meeting of Shareholders to approve the Business Report of the
year  ending 31 December 2012 will be held on 18 April 2013 at 14.00 CEST at the
Congress Center, Messe Basel, Switzerland.

The  invitation has  been published  in the  Swiss Official  Gazette of Commerce
(Schweizerisches Handelsamtsblatt) and is available, together with the company's
Annual Report, on www.actelion.com.

In  order to  attend and  vote at  the Annual  General Meeting  of Shareholders,
shareholders  must have been registered in the Company's shareholder register by
9 April 2013 at the latest.



                                      ###



NOTES TO EDITORS

ABOUT MR JOHN J. GREISCH

Mr.  John J.  Greisch is  currently President  (as Executive Director) and Chief
Executive  Officer of  Hill-Rom Holdings,  Inc., a  leading medical  supplier of
patient  support  systems  such  as  hospital  beds,  therapeutic  surfaces  and
stretchers.  Under Mr. Greisch's leadership,  Hill-Rom increased its investments
in  research  and  development,  introducing  new  smart  bed technology and new
surfaces  to the  market as  well as  expanding its Singapore-based Asia-Pacific
Innovation Center.

Before  joining Hill-Rom, Mr. Greisch spent seven years at Baxter International,
Inc. in various executive positions in corporate finance, operations and general
management.  From  2004-2006, he  served  as  Chief  Financial  Officer and from
2006-2009 as President International Operations.

Mr  Greisch earned a Bachelor's degree in Business Administration from the Miami
University,  US and  a Master's  Degree in  Management (MBA equivalent) from the
Northwestern University in Illinois, US

Mr. Greisch also serves on the Board of Lurie Children's Hospital in Chicago and
is  a past member of  the Business School Advisory  Board for Miami University's
Farmer School of Business.



ABOUT ACTELION LTD.

Actelion  Ltd is a biopharmaceutical company  with its corporate headquarters in
Allschwil/Basel,  Switzerland.   Actelion's  first  drug  Tracleer®,  an  orally
available  dual endothelin receptor  antagonist, has been  approved as a therapy
for pulmonary arterial hypertension.  Actelion markets Tracleer® through its own
subsidiaries  in key  markets worldwide,  including the  United States (based in
South   San  Francisco),  the  European  Union,  Japan,  Canada,  Australia  and
Switzerland.

Founded  in late 1997 Actelion is a leading player in innovative science related
to  the endothelium -  the single layer  of cells separating  every blood vessel
from  the blood stream.  Actelion's over 2,400 employees focus on the discovery,
development  and  marketing  of  innovative  drugs for significant unmet medical
needs.  Actelion shares  are traded  on the  SIX Swiss  Exchange (ticker symbol:
ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®).

For further information please contact:

Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com


Media Release PDF: 
 hugin.info/131801/R/1685097/551972.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
[HUG#1685097]